
SpringWorks Therapeutics’ Nirogacestat Granted Priority Review by FDA for Desmoid Tumor Treatment
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, has received acceptance from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for nirogacestat, an i ...